At ASTRO 2015, Mevion highlighted the exceptional results its customers are seeing with the Mevion S250 Series proton therapy system.
VIDEO: Explaining Boron Neutron Capture Therapy for Targeted Cancer Radiotherapy
Bruce Bauer, Ph.D., CEO of TAE Life Sciences. The company is developing boron neutron capture therapy (BNCT) as a new radiation therapy for cancer. A patient is first infused with a non-toxic boron-10 compound, which selectively accumulates in tumor tissue. A neutron beam is then focused on the tumor and the neutrons are captured by the boron and causes emission of alpha radiation particles within the tumor. Alpha particles have a a very short range, so this helps spare surrounding healthy tissue from radiation damage.
Historically, BNCT clinical studies have been carried out using boronophenylalanine (BPA) and neutrons derived from the core of a nuclear reactor. While the clinical outcomes have been encouraging, the availability of better boron-10 compounds and access to a neutron source posed a significant barrier to clinical research and adoption of BNCT as a practical cancer therapy.
There is now a renaissance in BNCT with the availability of new accelerator-based neutrons sources and novel synthesis of boron-10 target drugs, allowing clinical research to expand with the goal to have BNCT available as a new treatment option for patients.
The secondary radiation reaction from BNCT, with cellular-level precision, spares more healthy tissues and can potentially treat cancers that otherwise have few treatment options.
The system requires a neutron accelerator, but this is smaller than a proton system and operates at much lower energy, so the shielding requirement is much lower, cutting construction costs.
Varian offered an overview of its new technology offerings at ASTRO 2015. These include advancements in analytics, treatment planning, adaptive therapy, clinical decision support and new tools for the integration of MRI and PET/CT into the treatment planning process.
Learn more about myQA, IBA’s unique platform that connects QA applications, people, and know-how through a central database and the Cloud. It offers full support throughout all of your QA, and enables you access to the different software modules and all of your data from one intuitive interface – anywhere and anytime.
This brief video highlights the grassroots effort from IBA Dosimetry to satisfy customers through value added services and benefits that continue throughout the life cycle of their products, and beyond.
Joseph Deasy, Ph.D., discusses his study on dose-volume relations for late rectal bleeding in 1,001 patients from five prostate cancer cohorts with Imaging Technology News Editorial Director Melinda Taschetta-Millane.
American Association of Physicists in Medicine (AAPM) President John Boone, Ph.D., discusses the impact of imaging in medical physics, as well as key topics addressed at this year’s meeting, with Imaging Technology News Editorial Director Melinda Taschetta-Millane.
Detecting metastatic disease early is key. Sand Lake Imaging, Florida, provides great value to both patients and referrers by using syngo.via's efficient AV tools. See how!
The new syngo.via from Siemens Healthcare supports oncological treatment decisions across modalities, therapies and departments to enable state-of-the-art cancer care, increased competitiveness, and high referrer and patient satisfaction. syngo.via can be used as a standalone device or together with a variety of syngo.via-based software options, which are medical devices in their own right. syngo.via VB10 and the syngo.via VB10 based software options are currently under development, and not for sale in the U.S., China and other countries. Due to regulatory reasons its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.
Volpara now offers products to track breast density in mammography, X-ray radiation dose and analytical data. The company now integrates with tomosynthesis 3-D mammo systems. The technology has installations in 31 countries.
From the floor at this year's annual meeting of the American Society for Radiation Oncology (ASTRO), Chris Toth, vice president of global marketing and Americas sales at Varian Medical Systems, talks about the latest Varian technologies and how they can help enhance knowledge sharing among oncology care professionals. In the constantly evolving healthcare landscape, learn why Varian is developing leading edge solutions designed to help clinicians leverage data to improve the quality and consistency of care. Varian is creating a knowledge-based network, enabling clinical partners to share information, ideas, and best practices. Toth explains how InSightive Analytics, Varian's latest in a line of recently released informatics products, helps clinics dive deep into existing data in order to achieve actionable insights. Being able to explore, visualize, and aggregate critical data using InSightive can help improve operations as well as clinical care.
Suzanne Shankle, IBA product marketing specialist, explains how Dolphin helps provide better care and gives online control and confidence of treating patients safely.
Introducing HYPERSCAN , Pencil Beam Scanning Delivery HYPERSCAN enables tumor volumes to be scanned in a matter of seconds, benefiting from the MEVION S250's direct and efficient beam generation. The result is a fast Pencil Beam Scanning enabling robust Intensity Modulated Proton Therapy treatment delivery that is much less sensitive to patient and tumor motions, ultimately increasing the efficacy of the treatment procedure. The MEVION S250 proton therapy platform with HYPERSCAN allows you to treat with precision, accuracy and reproducibility at unparalleled speed with uncompromised beam quality. Designed for greater access by any size cancer care facility, the MEVION S250 significantly reduces the complexity, size, and cost associated with conventional proton therapy systems. The MEVION S250 is specifically engineered as upgrade-ready to continue providing the most advanced proton therapy treatment available today as well as tomorrow. Key Features : Field-Upgradeable; Streamlined Clinical Workflow with Full OIS Integration; High-Accuracy Beam Pointing with Submillimeter Position Tracking; Fast Volumetric and Layer Rescanning Capabilities; Supports Standard Gating Interface for Beam On/Off Hold
Kettering's oncolcogy services worked with Elekta to provide the latest radiation therapy with the Veras HD system.
AAPM President John E. Bayouth, Ph.D., discusses the impact of imaging in medical physics, as well as training that is available through AAPM, with Imaging Technology News Editorial Director Melinda Taschetta-Millane.
Peter G. Maxim, Ph.D., assistant professor of radiation oncology at Stanford University, discusses stereotactic radiotherapy for renal sympathetic nerve ablation for the treatment of refractory hypertension, and some of the challenges involved, with Imaging Technology News Editorial Director Melinda Taschetta-Millane.
Paul Keall, Ph.D., FAAP, professor and NHMRC Australian Fellow at Radiation Physics Laboratory at the University of Sydney, Sydney Medical School, discusses radiosurgery beyond cancer. He explains how radiotherapy might be used to ablate cardiac tissue noninvasively, which could eliminate the need for the current invasive, catheter-based ablation therapies used in electrophysiology.
Kettering Medical Center Therapist, Sarah Macke, describes how their center improved their treatment process with safety and efficiency by using the Elekta Versa HD system.
Varian Medical Systems celebrates its 65-year anniversary, focused around innovation, partnership, collaboration and service. As it looks to the next 65 years, the company's vision is focused on a world without fear of cancer. Varian's goal is to work closely with the clinical community to help remove fear, provide better tools and also software solutions that will improve care over time. At ASTRO 2013, Varian highlighted what is new this year: The first installations of the Edge Radiosurgery Suite CT on Rails solution for brachytherapy, in partnership with Siemens' Aria and Eclipse Version 11, with over 500 installations to date; Connectivity to Siemens accelerators currently in the process of regulatory filing; Launch of RapidPlan Knowledge-based planning system
Varian Medical Systems launched RapidPlan Knowledge-based Planning at ASTRO 2013. RapidPlan is a new paradigm for treatment planning that will change the way planning is done by helping facilities capture actual clinical practices based on treatment plans that have been done in the past. RapidPlan will help busy clinics increase efficiency overall for the treatment planning process. For clinics new to the technology, models from other clinics can be used, applying past learning experiences to their own model. And with academic medical centers, RapidPlan is a great tool for narrowing the variations between the different clinicians within the practice itself.
Esteya electronic brachytherapy by Nucletron, an Elekta company, is a new, high-precision treatment solution for treating skin cancer. Esteya mimics high dose rate (HDR) brachytherapy by bringing a miniaturized X-ray source very close to the cancerous site, enabling the local application of radiation for effective treatment. By virtue of this direct delivery, Esteya can concentrate more therapeutic radiation to the disease target and minimize radiation to the surrounding tissues and organs. Notably, Esteya requires only minimal room shielding and features a compact design and exceptional mobility, allowing the treatment to occur virtually anywhere patients are seen. Esteya represents a desirable alternative to surgery, the therapy that patients most commonly select to treat their skin cancer. Esteya features: Patient-friendly design, with a high dose rate that enables treatment delivery in less than three minutes; user-centric operation, offering a highly efficient workflow and easy patient set-up; and attractive economic profile
AAPM President John Hazle, Ph.D., discusses trends in medical physics and major initiatives that the association is addressing in 2014 with Imaging Technology News Editorial Director Melinda Taschetta-Millane.
Varian introduced the Edge radiosurgery Suite during ASTRO 2012. The system features real-time tumor tracking and a six-degree of freedom couch.
At ASTRO 2012, IBA featured a scale model install of its Proteus One compact proton system combined with the Philips Ambient Experience, designed to count patients through lighting visual effects.
At ASTRO 2012, Mevion featured its compact Mevion S250 Proton Therapy System, which has a footprint comparable to traditional radiation therapy systems.
At ASTRO 2012, Ray Search Americas demonstrated the latest features for its radiation therapy treatment planning system.
Dr. Gary Ezzell, president of the American Association of Physicists in Medicine (AAPM), talks about current trends in medical physics, particularly the melding of imaging and radiation therapy to guide treatment. He also recaps some of the hot topics discussed at this year's annual meeting in Charlotte, N.C., and AAPM's key initiatives for the coming year.
IBA Dosimetry offers commissioning services for linear accelerators (linacs), using state-of-the-art equipment like the Blue Phantom and the linear diode array. A variety of service options are available, from a turnkey operation to segmented individual services or post-installation support, depending on the customer's needs. Utilizing these services can help a clinic get up-and-running in the quickest time possible. Customers also can utilize IBA's new International Competence Center (ICC) to receive training to do commissioning on their own. For more information, visit www.iba-dosimetry.com
Gary Levine, M.D., program chair/incoming president of the National Consortium of Breast Centers, discusses the emergence of interoperative radiation therapy (IORT) at the 22nd annual National Interdisciplinary Breast Center Conference (NCoBC), held in Las Vegas in March.
Michael L. Steinberg, M.D., incoming president of the American Society for Radiation Oncology (ASTRO), presents highlights of the 2011 annual meeting, including an overview of educational programs and scientific sessions held during the event. Presentations included study findings regarding IMRT versus other forms of radiation therapy treatment for prostate cancer, as well as a study regarding hypofractionation of prostate cancer to decrease treatment time. Steinberg also describes some of ASTRO's other activities and gives his thoughts about challenges facing the membership during the coming year.
For more information: www.astro.org
IBA ProteusONE offers uncompromised treatment solutions enabling physicians to leverage the clinical effectiveness of proton beam therapy. While Pencil Beam Scanning enables the delivery of Intensity Modulated Proton Therapy (IMPT) treatment plans, the latest imaging techniques make Image Guided Proton Therapy (IGPT) possible. ProteusONE has been inspired by everyday clinical practice. Its design enhances the patient experience by fostering a soothing environment while making the medical staff's daily practice safer and easier. Finally ProteusONE is IBA's response to making protons affordable. It is a proton therapy system that is smaller, more affordable, easier to install, easier to operate and ultimately easier to finance. With ProteusONE, protons are possible for more patients worldwide.
For more information: www.iba-worldwide.com
IBA showcased its noninvasive radiation oncology treatment systems during the American Association of Physicists in Medicine (AAPM) 2011 annual meeting. This included its new Proteus One proton therapy system, advanced dose management and the addition of cone-beam computed tomography (CT) to help guide therapy.
For more information: www.IBA-protontherapy.com
Tony Seibert, Ph.D., president of the American Association of Physicists in Medicine (AAPM), explained the key initiatives of the group during its 2011 annual meeting. These include:
• AAPM is working with its members to reduce patient radiation dose across radiology modalities.
• It is developing physics-based Web training modules for diagnostic radiology residents.
• Members are working to create residency programs for both radiation therapy and diagnostic radiologists.
• AAPM is also working with several states to create license certification programs to ensure who is a qualified medical physicist.
For more information: www.aapm.org
At ASTRO 2010, one of the big topics was how radiation oncology as a profession is in a period of retrenchment due to the economic crisis. There is also a growing demand from payors to show value for these treatments, said American Society for Radiation Oncology (ASTRO) President Anthony Zeitman, M.D., director, Harvard Radiation Oncology Residency Program, Jenot and William Shipley Professor of Radiation Oncology at Harvard Medical School. He said the radiotherapy technologies used need to undergo rigorous clinical testing to show what technologies and techniques work best and what is most cost-effective. Part of ASTRO's push is for a national registry to help advance this data collection.
IBA introduced its new Proteus One proton treatment system during ASTRO 2010. It is about one-third the size of current proton treatment systems, taking up about the same amount of space as two linac rooms side-by-side. The Proteus One is designed to offer more patient access to proton therapy by making the treatment system easier to install. It is also designed to be used as a single treatment room installation, rather than sharing a larger cyclotron and beam with several treatment rooms. For more information: www.iba-worldwide.com
American Association of Physicists in Medicine (AAPM) President Mike Herman, Ph.D., radiation oncology medical physicist, Mayo Clinic, explains the role of the society and its goal to improve patient care. Activities include sharing the latest scientific research, developing best practices, education, setting guidelines for certification and the roles of various staff under mediacl physicists, and how physicists can better serve their hospitals. The main focus in sessions at the AAPM annual meeting include patient safety concerning radiation dose and how to lower these doses in practice. Herman said AAPM is also calling for a national patient safety event recording process to make it easier to see where there are mistakes so they can be addressed. The society is also Herman said the process needs to be easy to access and use. He spoke to ITN at the some 2010, 52nd annual AAPM meeting